Can Platelet Function Tests Predict the Clinical Efficacy of Aspirin?

 

 Buy Article Permissions and Reprints

ABSTRACT

“Aspirin resistance” and “aspirin nonresponsiveness” are terms used both to describe both the failure of aspirin to protect subgroups of individuals from severe vascular events and to evoke an appropriate inhibition of platelet function. Several studies utilizing a broad range of platelet function tests have shown that some subgroups of individuals exhibit a reduced or completely missing antiplatelet response to aspirin. The clinical significance of aspirin nonresponsiveness for the prediction of clinical endpoints remains, however, to be determined. Thus far, only three prospective clinical trials have demonstrated a possible relationship between aspirin nonresponsiveness and subsequent vascular events. Most platelet function tests used in respective clinical studies cannot be reliably performed in clinical routine and are not interchangeable for monitoring antiplatelet treatment. There is a need for a simple and reliable assay for predicting the clinical efficacy of antiplatelet therapy. Recent data demonstrate that none of the currently developed assays, including the PFA-100 system, are presently able to accomplish these objectives.

REFERENCES

• 1 Schrör K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.  Semin Thromb Hemost. 1997;  23 349-356
  PubMedGoogle Scholar
• 2 Steering Committee of the Physicians’ Health Study Research Group . Final report on the aspirin component of the ongoing Physicians’ Health Study.  N Engl J Med. 1989;  321 129-135
  CrossrefPubMedGoogle Scholar
• 3 Antithrombotic Trialists’ Collaboration . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.  BMJ. 2002;  324 71-86
  CrossrefPubMedGoogle Scholar
• 4 Patrono C, Coller B, Dalen J E et al.. Platelet active drugs. The relationships among dose, effectiveness, and side effects.  Chest. 2001;  119 39S-63S
  CrossrefPubMedGoogle Scholar
• 5 Cambria-Kiely J A, Gandhi P J. Aspirin resistance and genetic polymorphisms.  J Thromb Thrombolysis. 2002;  14 51-58
  CrossrefPubMedGoogle Scholar
• 6 McKee S A, Sane D C, Deliagyris N. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance.  Thromb Haemost. 2002;  88 711-715
  PubMedGoogle Scholar
• 7 Howard P A. Aspirin resistance.  Ann Pharmacother. 2002;  36 1620-1624
  CrossrefPubMedGoogle Scholar
• 8 Halushka M K, Walker L P, Halushka P V. Genetic variation in cyclooxygenase-1: effects on response to aspirin.  Clin Pharmacol Ther. 2003;  73 122-130
  CrossrefPubMedGoogle Scholar
• 9 Grotemeyer K H, Scharafinski H W, Husstedt I W. Two-year follow-up of aspirin responder and aspirin non responder. A pilot study including 180 post-stroke patients.  Thromb Res. 1993;  71 397-403
  CrossrefPubMedGoogle Scholar
• 10 Mueller M R, Salat A, Stangl P et al.. Variable platelet response to low-dose ASA and the link of limb deterioration in patients submitted to peripheral arterial angioplasty.  Thromb Haemost. 1997;  78 1003-1007
  PubMedGoogle Scholar
• 11 Gum P A, Kottke-Marchant K, Welsh P A, White J, Topol E J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.  J Am Coll Cardiol. 2003;  41 961-965
  CrossrefPubMedGoogle Scholar
• 12 Born G VR. Aggregation of blood platelets by adenosine diphosphate and its reversal.  Nature. 1962;  194 927-929
  PubMedGoogle Scholar
• 13 Born G V, Dearnley R, Foulks J G, Sharp D E. Quantification of the morphological reaction of platelets to aggregating agents and of its reversal by aggregation inhibitors.  J Physiol. 1978;  280 193-212
  PubMedGoogle Scholar
• 14 Cardinal D C, Flower R J. The electronic aggregometer: a novel device for assessing platelet behaviour in blood.  J Pharmacol Methods. 1980;  3 135-158
  CrossrefPubMedGoogle Scholar
• 15 Wu K K, Hoak J C. A new method for quantitative detection of platelet aggregates in patients with arterial insufficiency.  Lancet. 1974;  22 924-926
  PubMedGoogle Scholar
• 16 Grotemeyer K H. The platelet reactivity test. A useful by-product of the blood sampling procedure?.  Thromb Res. 1991;  61 423-431
  CrossrefPubMedGoogle Scholar
• 17 Hurlen M, Seljeflot I, Arnesen H. The effect of different antithrombotic regimens on platelet aggregation after myocardial infarction.  Scand Cardiovasc J. 1998;  32 233-237
  CrossrefPubMedGoogle Scholar
• 18 Kratzer M A, Born G V. Simulation of primary haemostasis in vitro.  Haemostasis. 1985;  15 357-362
  PubMedGoogle Scholar
• 19 Gum P A, Kottke-Marchant K, Poggio E D et al.. Profile and prevalence of aspirin resistance in patients with cardiovascular disease.  Am J Cardiol. 2001;  88 230-235
  CrossrefPubMedGoogle Scholar
• 20 Eikelboom J W, Hirsh J, Weitz J I, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events.  Circulation. 2002;  105 1650-1655
  CrossrefPubMedGoogle Scholar
• 21 Weber A A, Przytulski B, Schanz A, Hohlfeld T, Schör K. Towards a definition of aspirin resistance: a typological approach.  Platelets. 2002;  13 37-40
  CrossrefPubMedGoogle Scholar
• 22 Breddin K, Ziemen M, Bauer O et al.. Time and temperature dependent changes of ADP- and collagen-induced and “spontaneous” aggregation.  Thromb Res. 1980;  19 621-638
  CrossrefPubMedGoogle Scholar
• 23 Nicholson N S, Panzer-Knodle S G, Haas N F et al.. Assessment of platelet function assays.  Am Heart J. 1998;  135 S170-S178
  CrossrefPubMedGoogle Scholar
• 24 Sane D C, McKee S A, Malinin A I, Serebruany V L. Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin.  Am J Cardiol. 2002;  90 893-895
  CrossrefPubMedGoogle Scholar
• 25 Helgason C M, Tortorice K L, Winkler S R et al.. Aspirin response and failure in cerebral infarction.  Stroke. 1993;  24 345-350
  PubMedGoogle Scholar
• 26 Helgason C M, Bolin K M, Hoff J A et al.. Development of aspirin resistance in persons with previous ischemic stroke.  Stroke. 1994;  25 2331-2336
  CrossrefPubMedGoogle Scholar
• 27 Weksler B B, Kent J L, Rudolph D, Scherer P B, Levy D E. Effects of low dose aspirin on platelet function in patients with recent cerebral ischemia.  Stroke. 1985;  16 5-9
  PubMedGoogle Scholar
• 28 Berglund U, Wallentin L. Persistent inhibition of platelet function during long-term treatment with 75 mg acetylsalicylic acid daily in men with unstable coronary artery disease.  Eur Heart J. 1991;  12 428-433
  PubMedGoogle Scholar
• 29 Kundu S K, Heilmann E J, Sio R, Garcia C, Ostgaard R A. Description of an in vitro platelet function analyzer, PFA-100.  Semin Thromb Hemost. 1995;  21 106-112
  PubMedGoogle Scholar
• 30 Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital and acquired platelet dysfunction.  J Lab Clin Med. 2001;  138 152-163
  CrossrefPubMedGoogle Scholar
• 31 Mammen E F, Comp P C, Gosselin R et al.. PFA-100 system: a new method for assessment of platelet dysfunction.  Semin Thromb Hemost. 1998;  24 195-202
  Article in Thieme ConnectPubMedGoogle Scholar
• 32 Fressinaud E, Veyradier A, Truchoud I et al.. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases.  Blood. 1998;  91 1325-1331
  CrossrefPubMedGoogle Scholar
• 33 Böck M, de Haan J, Beck K H et al.. Standardization of the PFA-100 platelet function test in 105 mmol/L buffered citrate: effect of gender, smoking, and oral contraceptives.  Br J Haematol. 1999;  106 898-904
  CrossrefPubMedGoogle Scholar
• 34 Macchi L, Christiaens L, Brabant S et al.. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate.  Thromb Res. 2002;  107 45-49
  CrossrefPubMedGoogle Scholar
• 35 ten Berg J M, Gerritsen W BM, Haas F JLM, Kelder H C, Verheugt F W, Plokker H W. High-dose aspirin in addition to daily low-dose aspirin decreases platelet activation in patients before and after percutaneous coronary intervention.  Thromb Res. 2002;  105 385-390
  CrossrefPubMedGoogle Scholar
• 36 Hézard N, Metz D, Nazeyrollas P, Droulle C, Potron G, Nguyen P. PFA-100 and flow cytometry: can they challenge aggregometry to assess antiplatelet agents, other than GPIIbIIIa blockers, in coronary angioplasty?.  Thromb Res. 2002;  108 43-47
  CrossrefPubMedGoogle Scholar
• 37 Harrison P. Progress in the assessment of platelet function.  Br J Haematol. 2000;  111 733-744
  PubMedGoogle Scholar
• 38 Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100.  Thromb Haemost. 2000;  83 316-321
  PubMedGoogle Scholar
• 39 Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks.  J Neurol. 2003;  250 63-66
  CrossrefPubMedGoogle Scholar
• 40 Grotemeyer K H. Effects of acetylsalicylic acid in stroke patients-evidence of nonresponders in a subpopulation of treated patients.  Thromb Res. 1991;  63 587-593
  CrossrefPubMedGoogle Scholar
• 41 FitzGerald G A, Pedersen A K, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease.  Circulation. 1983;  67 1174-1177
  PubMedGoogle Scholar
• 42 Granström E. Methodology in prostaglandin and thromboxane assay.  Prog Lipid Res. 1986;  25 119-127
  PubMedGoogle Scholar

Peter HellsternM.D. 

Institute of Hemostaseology and Transfusion Medicine, Academic City Hospital

D-67063 Ludwigshafen, Germany

Email: peterhellstern@medicusnet.de